Statistics
Total Visits
| Views | |
|---|---|
| Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study | 182 |
Total Visits Per Month
| March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | August 2024 | September 2024 | |
|---|---|---|---|---|---|---|---|
| Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study | 17 | 1 | 2 | 4 | 1 | 7 | 3 |
Top country views
| Views | |
|---|---|
| United States | 84 |
| Poland | 62 |
| Sweden | 8 |
| China | 5 |
| France | 5 |
| Cyprus | 2 |
| Germany | 2 |
| Ireland | 2 |
| Argentina | 1 |
| Canada | 1 |
Top cities views
| Views | |
|---|---|
| Warsaw | 62 |
| San Mateo | 17 |
| Louisville | 11 |
| Boardman | 9 |
| Des Moines | 7 |
| San Ramon | 7 |
| Ann Arbor | 4 |
| Ashburn | 4 |
| Beijing | 4 |
| Redwood City | 4 |